Resolve Therapeutics (Seattle, WA), a preclinical-stage biotechnology company focused on the development of lupus treatments, closed a $5.8M Series B financing. Participants include New Science Ventures, Easton Capital and WRF Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive […]
Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.